L. Masae Kawamura, M.D. Senior Director, Medical and Scientific Affairs, Tuberculosis Clinician, San Francisco TB Clinic DISCLAIMER
|
|
- Evangeline Richard
- 5 years ago
- Views:
Transcription
1 IGRA update QuantiFERON -TB Gold Plus (QFT-Plus) L. Masae Kawamura, M.D. Senior Director, Medical and Scientific Affairs, Tuberculosis Clinician, San Francisco TB Clinic October, 2018 DISCLAIMER I am employed by QIAGEN, manufacturer of QFT and other diagnostics, however the views expressed are my own and not necessarily the views of QIAGEN Global Tuberculosis Report 2017, WHO 1
2 Tuberculin skin test (TST) IGRA: ELISA IGRA example Manual placement, reading and data entry Results affected by BCG vaccine and NTM Two patient visits required, high no-show rate Significant inter-reader variability Poor surveillance tool Often no quality control after initial training Boosted reactions confound serial testing Can be fully automated (QFT-Plus) Highly specific, not affected by BCG Results with one patient visit No inter-reader variability (QFT-Plus) Electronic results (straight to EMR) Quality-assured laboratory NO boosting from serial IGRAs TST is a not patient or program centered assay, especially in the populations relevant to TB control 3 Evolution of ELISA IGRA Technology 1 st generation QuantiFERON -TB 2 nd generation QuantiFERON -TB Gold (liquid antigen) 3 rd generation QuantiFERON -TB Gold (QFT in tube) 4 th generation QuantiFERON -TB Gold Plus (QFT -Plus) 2001: FDA approval 2004: FDA approval 2007: FDA approval Measured cell-mediated immunity to tuberculin purified protein derivative (PPD) Breakthrough: TST becomes a blood test Liquid antigen version Antigens specific for M.tb with 99% specificity New benchmark: No cross reactivity with BCG Logistical advantage remote incubation New benchmark: Scalable and easily automated >1500 peer reviewed publicatoins >30 million tests sold Q4 2014: CE-IVD 2017: FDA approved New benchmark: Addition of patented CD8 antigens potential biomarker of intracellular TB burden New flexible blood draw options 4 2
3 QFT Publications prior to QFT-Plus ~1500 published studies with key articles showing important utility in testing high risk groups BCG-vaccinated Migrants to US HIV Biologics Pediatrics Pregnancy Contacts Risk of Progression End Stage Renal Gao L et al, Lancet Infect Dis Mar; 15(3): Epub 2015 Feb Howley MM et al. Pediatr Infect Dis J Aug 4. Painter JA et al. PLoS One Dec 19;8(12):e Riazi S et al. Allergy Asthma Proc May-Jun;33(3): Howley MM et al. Pediatr Infect Dis J Aug 4. Painter JA et al. PLoS One Dec 19;8(12):e Sorborg C et al. Eur Respir J Aug;44(2):540-3 Cheallaigh CN et al. PLoS One. 2013;8(1):e Aichelburg MC et al. Clin Infect Dis Apr 1;48(7): Raby E et al. PLoS One Jun 18;3(6):e2489. Hsia EC et al. Arthritis Rheum Jul;64(7): Ponce De Leon D et al. J Rheumatol May;35(5): Matulis G et al. Ann Rheum Dis Jan;67(1): Jason Andrews et al, Lancet Respir Med Apr;5(4): Mandalakas A et al, AJRCCM, Vol 191: Garazzino S et al. Pediatr Infect Dis J Sep;33(9):e Howley MM et al. Pediatr Infect Dis J Aug 4. Sollai et al. BMC Infectious Diseases 2014, 14 (Suppl 1):S6 LaCourse SM et al. J Acquir Immune Defic Syndr Jan 30. doi: Mathad JS et al. AJRCCM online.published on 14-January-2016, /rccm OC Mathad JS et al. PLoS One Mar 21;9(3):e Lighter-Fisher J, Surette AM. Obstet Gynecol Jun;119(6): Matsumoto K et al, Kekkaku Vol 91, No.2:45-48, 2016 Li CY et al, Journal of Microbiology, Immunology and Infection (2015) 48, 263e268 Zellweger et al, Loddenkemper et al., AJRCCM, 12 March 2015 Diel R et al. Am J Respir Crit Care Med Jan 1;183(1): Arend SM et al. Am J Respir Crit Care Med Mar 15;175(6): Gao L et al, Lancet Infect Dis Jul 14. pii: S (17) doi: /S (17) Jason Andrews et al, Lancet Respir Med Apr;5(4): Altet N et al, Ann Am Thorac Soc 2015 May;12(5):680-8 Soborg C et al. Eur Respir J Aug;44(2): Diel R et al. Chest Jul;142(1): Rogerson TE et al. Am J Kidney Dis Jan;61(1): What we know from >decade of IGRA use:. IGRAs = Replacing most TST use in TB programs in the US, many countries of W. Europe, Japan, Taiwan, Singapore, and Korea IGRAs are superior to TST in BCG vaccinated populations in both children and adults (sensitivity, specificity and PPV) QFT performs consistently in high risk populations and correlate better to risk than the TST IGRAs = cost effective compared to TST eliminate unnecessary radiation exposure, medical exams, and medical error from unnecessary treatment IGRA operational advantages = convenience for patients and higher quality care 3
4 There is no gold standard for LTBI (no direct evidence) LEVELS OF PROOF for test accuracy Efficacy of preventive therapy Stronger Predictive value for active TB Correlation to exposure gradient Sensitivity/spec for active TB Concordance with TST Weakest 7 Key study: Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China (Gao et al, Lancet ID 2017) 2 year follow up study on multi-center cohort: QFT+ or TST+ ( 10mm) 2013: Baseline LTBI prevalence (n=21,022) QFT 18% (13-20%) TST 28% (15-42%) : tracked disease progression by test positivity n=7505 QFT+ (n=4455) TST+ (n=6404) TST+/QFT- (n=3050) TST-/QFT+ (n=1101) TST+/QFT+ (n=3354) Incidence n Cumulative incidence* (95% CI) 1.68% ( ) 0.97% ( ) 0.30% ( ) 2.0% ( ) 1.58% ( ) Incidence/100 person years* (95% CI) 0.87 ( ) 0.50 ( ) 0.16 ( ) 1.03 ( ) 0.82 ( ) *P=< *P=< key populations in communities in rural China could be targeted for latent infection screening and treatment with an IGRA rather than the TST. Gao L et al, Lancet Infect Dis 2017; 17:
5 4th Generation: QuantiFERON-TB Gold Plus SAME test principle-procedure..same technology of QFT QFT-Plus is an improved version of QFT that is replacing QFT-GIT : Sensitivity of ~94% in registration trials Specificity of >97% Innovative CD8 + T-cell stimulating antigens added Optimized for CD4 + and CD8 + response Improvements in test formulation and manufacturing Flexible blood draw options NEW: One Li-heparin tube draw approved for transfer into QFT-Plus tubes NEW: 2 day time limit for blood collection to incubation if Li-heparin tube stored between 2-8 degrees C QFT-Plus: potential test evolution CD8 Antigens 9 Indeterminate rates when using single tube Lithiumheparin blood draw Studies using single tube collection followed by blood transfer to QFT-tubes and immediate incubation Siegel, JCM 2018 QFT-Plus Study N Indeterminate rate QIAGEN clinical trials Package insert 2018 QFT-Plus Gallagher David, Synlab publication 2015, QFT-GIT 263 Oregon US low risk specificity trial including 51 pts with NTM USA, 322 Japan and 199 from Australia (all no risk for TB) 4615 UK migrant clinics study, multiple sites 1/ % 0/733 Zero 10/ % 10 5
6 New CD8 + antigens: WHY? CD8+ T cells and role in TB immunity: MTB-specific CD8 + T cells secrete IFN- and other soluble factors to (1 3): Suppress MTB growth Kill infected cells Directly lyse intracellular MTB BIOMARKER for intracellular burden TB-specific CD8 + T cells that produce IFN- have been: More frequently detected in those with active TB disease vs. latent infection (4, 5) Associated with recent exposure to TB (6) Detectable in active TB subjects with HIV co-infection and young children (7, 8) Observed to decline when patients are exposed to anti-tuberculosis treatment (9) References: 1. Turner, J. et al. (1996) Immunology 87, Brookes, R.H. et al. (2003) Eur. J. Immunol. 33, Stenger, S. et al. (1998) Science 282, Day, C.L. et al. (2011) J. Immunol. 187, Rozot, V. et al. (2013) Eur. J. Immunol. 43, Nikolova, M. et al. (2013) Diagn. Microbiol. Infect. Dis. 75, Chiacchio, T. et al. (2014) J. Infect Lanicioni, C. et al. (2012) Am. J. Respir. Crit. Care Med. 185, Nyendak M. Et al. (2014) PLoS ONE 8, e Epub. 11 QuantiFERON TB Gold In tube Nil control TB Antigen Mitogen control QuantiFERON TB Gold Plus Nil control TB 1 Antigen TB2 Antigen Mitogen control Cells stimulated none CD4+ T-Cells All none CD4+ T-Cells CD4+ and CD8+ T-Cells All Polypeptide Antigens Long peptides (MHC class II) ESAT-6 CFP-10 TB7.7 Long peptides (MHC class II) ESAT-6 CFP-10 TB7.7 Long peptides (MHC class II) ESAT-6 CFP-10 TB7.7 + Additional short peptides (MHC class I) 2 Antigen tubes: More information: 2 data points instead of 1 Allows the calculation of CD8 response Title, Location, Date 12 6
7 QFT-Plus: Can it differentiate patients in the spectrum of TB? MTB specific CD4 T cells produce interferon gamma at all stages MTB specific CD8 T cells more readily detected as bacterial burden increases Infection eliminated With innate immune response With acquired immune response Latent TB infection Subclinical TB disease Active TB disease TST Negative Positive Positive Positive Usually positive IGRA Negative Positive Positive Positive Usually positive Culture Negative Negative Negative Intermittently positive Sputum smear Negative Negative Negative Usually negative Infectious No No No Sporadically Yes Positive Positive or negative Symptoms None None None Mild or non Mild to severe Preferred treatment None None Preventative therapy Multidrug therapy Multidrug therapy Pai, M. et al. (2016) Tuberculosis Nat. Rev. Dis. Primers doi: /nrdp The CD8 signal of QFT-Plus, if present, can provide an expanded picture of TB immunity 13 Additional analysis of TB Antigen Tube values Package Insert data TB2 Minus TB1 (i.e. CD8/CD4 CD4) TB2 TB1 (Nil subtracted) Surrogate for isolated CD8 response Is this is recent infection? Are they more likely to progress? Does this information help inform clinical practice? n=733 n=588 n=357 Potential for additional valuable information for risk stratification? 14 7
8 Multicenter study of QuantiFERON-TB Gold Plus in patients with active tuberculosis Horne D, Narita M et al, IJTLD, 22(6): , 2018 QFT-GIT Sensitivity 94.3% (vs %) (P=0.16) No statistical difference in sensitivity Agreement was 98.7%, Kappa 0.89 (CI ) QFT-GIT quantitative values higher than QFT-Plus Other findings: TB2 greater than TB1: 99/157 or 63% TB1 greater than TB2: 39/157 or 25% TB1 and TB2 equal: 16/157 or 10.2% Median difference between TB2 and TB1 (nil subtracted): 0.14 IU/ml PowerPoint Style Guide 15 WARNING: Lack of a CD8 response does not rule out TB disease or subclinical TB or TB that will progress However, the presence and strength of the CD8 response may help determine risk of progression or disease in the context of the patient scenario Note: There is no currently validated quantitative cut point or threshold for a significant CD8 response 16 8
9 Independent evidence: Sensitivity-Specificity 17 Sensitivity of QFT-Plus Published data (culture confirmed TB) Publication Indeterminate Sensitivity BARCELLINI et al, ERJ % (3/116) 87.93% (102/116) Includes 4/4 HIV infected HOFFMAN et al, CMI %(0/24) 95.8% (23/24) YI et al, Scientific Reports % (5/162) 91% (147/162) Takasaki, J Infect Chemother % (0/99) 99% (98/99) Horne, IJTLD % 7/164 89% (146/164) Fukushima, Kekkaku % 1/ % (72/77) TOTAL N= % 16/ % (588/642) Sensitivity meta-analyses (culture proven TB) QFT - GIT Sester et al. ERJ % Diel et al. Chest % 18 9
10 Specificity of QFT-Plus published data Publication N Specificity (negative/n) BARCELLINI et al, ERJ % (103/166) YI et al, Scientific Reports % (207/212) Moon et el, JCM Takasaki, J Infect Chemother US HCW no risk identified Siegel et al, IJTLD, (includes 51 with pulmonary NTM) 97.1% (607/625) % (104/106) 98.1% (257/262) TOTAL % (1021/1049) 19 Specificity of QFT-Plus Independent data Conservative positive definition in persons with no risk: concordant positive of bothtb1 and TB2 Publication N Specificity (negative/n) BARCELLINI et al, ERJ % (105/106) Moon et el, JCM US HCW no risk 99% (619/625). identified Takasaki, J Infect Chemother % (105/106) 2017 TOTAL % 829/ QuantiFERON-TB Gold Plus (QFT-Plus) ELISA Package Insert. Rev. 02. February
11 QFT-Plus: Clinical performance Specificity Studies FDA approved US Package Insert Overall No loss of specificity with QFT-Plus Total of 733 low-risk subjects Site N QFT QFT-Plus QFT-Plus (concordant positive) % Specificity (95% CI) Australia % ( ) Japan % ( ) Japan % ( ) USA % ( ) Overall % ( ) % Specificity (95% CI) 95.5% ( ) 97.7 % ( ) 98.1 % ( ) 98.1 % ( ) 97.3 % ( ) % Specificity (95% CI) 97.9 % ( ) 99.1 % ( ) % ( ) 99.1 % ( ) 98.9 % ( ) 21 Evidence: CD8 antigens in action 22 11
12 QuantiFERON-TB Gold Plus: Gaining attention in 2016 WHO TB report CD8 and CD4 T-cell response Current IGRA assays primarily detect a CD4 T-cell response. However, a new generation assay, the QuantiFERON-TB Plus (QFT- Plus, Qiagen, Hilden, Germany), has been developed to stimulate gamma interferon production by both CD4 and CD8 T-cells. First results indicate that the CD8 T-cell response may be able to identify people at greater risk of progression to active TB. QuantiFERON-TB Gold Plus: Potential to better identify risk for progression Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur Respir J. 2016:ERJ First evaluation of QuantiFERON-TB Gold Plus performance in contact screening TB2:TB1 differential as a surrogate measure for CD8 stimulation 15% of contacts had TB2-TB1 values >0.6 IU/mL (25% of those QFT+) Significantly associated with proximity to the index case p = Significantly associated with European origin p = Overall stronger risk association compared to QFT-GIT QFT-Plus in contact screening has improved performance compared to QFT-GIT... [QFT-Plus performance] suggests a role for the differential value between the two tubes as a proxy for recent infection. Barcellini et al, Eur Respir J Jul 7. pii: ERJ doi: / Epub ahead of print] 24 12
13 NEW! A multicentre verification study of the QFT-Plus ED Pieterman et al, Tuberculosis 108 (2018) Study objective: comparison QFT-Plus vs QFT-GIT in testing at-risk groups N= laboratories in Netherlands and Belgium Reason for screening N Positive by QFT- Plus TB suspicion /263 15% Contact /127 42% investigation Screening before /337 5% immunotherapy Occ health periodic 189 9/189 5% check* Other 57 13/57 23% Unknown 58 12/58 21% Percent with CD8 signal >0.6 IU/ml TB2-TB1 17% 33% 11% 33% 15% 33% The most striking observation of this study was that one third of all positive tested contact screening subjects had a true difference in *HCWs working with TB patients or possibly Mtb infected materials IFN γ release between TB1 and TB2 PowerPoint Style Guide 25 Evidence: QFT-Plus adding value in immunocompromised persons 26 13
14 1st evaluation of QFT-Plus performance in PLHIV (high-burden setting) Telisinghe et al. (2016) The sensitivity of the QuantiFERON -TB Gold Plus assay in Zambian adults with active tuberculosis. Int. J. Tuberc. Lung Dis. 21(6) Study design: Prospective recruitment of Zambian patients with pulmonarytb Mean age of 32, 73% male; 63% HIV infected, BMI <18.5 (>50%) 108 consecutive smear or Xpert + QFT-Plus results 108 Pulmonary TB patients 68 HIV-positive 39 smear+, 29 Xpert+ 40 HIV-negative 34 smear+, 6 Xpert+ 58 Positive 6 Negative 4 Indeterminate 32 Positive 5 Negative 3 Indeterminate 85% 6% 80% 8% QFT-Plus performance in PLHIV (high-burden setting) cont. QFT-Plus results not affected by HIV status Median IFN γ was higher in TB2 than in TB1 irrespective of HIV status HIV negative: 20% of negative/indeterminate results on TB1 were positive on TB2 HIV positive: 29% of negative/indeterminate results on TB1 were positive on TB2. QFT Plus negative/indeterminate (n=18) were associated with nutritional status (76% underweight) and not associated with HIV status Compared to prior study in their institution with similar cohorts (Raby 2007) QFT not affected by HIV status and less affected by low CD4 count (results in % below) Telisinghe et al, INT J TUBERC LUNG DIS 21(6):
15 3-way comparison: QFT-Plus, QFT-GIT and T-Spot in active TB K. Fukushima et al, Kekkaku, Vol. 93, No. 10: , 2018 N= 77 culture or LAMP/PCR proven pulmonary TB patients Average 80 years old T-SPOT cut point =8 spots (blood age >8hrs with additive T-cell Xtend) Assay Sensitivity (%) Indeterminate or invalid (%) QFT-Plus** 72/77 (93.5) 1 (1.3) QFT-GIT 70/77 (90.9) 3 (3.9) T-SPOT 57/77 (74.0)* 6 (7.8) **2 of the 3 QFT-GIT indeterminates were positive for QFT-plus due to positive TB2 tube Sensitivity by assay N=20 <age 80 N=57 >age80 N=23 CD4<200 QFT-Plus (%) QFT-GIT (%) * T-Spot (%) * *statistically significant p<0.05 from both QFTs QFT-plus had the highest sensitivity in all age groups and was significantly higher than Elispot in active TB, elderly patients (p<0.005) and those with low CD4 29 NEW! ELISA-IGRA study in the elderly Quantiferon-TB Gold Plus is a More Sensitive Screening Tool than Quantiferon-TB Gold In-Tube for Latent Tuberculosis Infection among Older Adults in Long-Term Care Facility Jung Yien Chien et al, J. Clin. Microbiol. doi: /jcm , Posted Online 23 May 2018 Study Design: QFT-GIT/QFT-Plus comparison study LTBI sensitivity, specificity, PPV and NPV derived from reproducible positive results N=229 51% male Median age 80 yrs ( yrs) Positive results Sensitivity Specificity PPV NPV QFT-GIT 28.8% 89.4% 95.7% 89.4% 95.7% QFT-Plus 32.3% 100%* 95.1% 89.2% 100%* Key findings: *P<0.05 QFT Plus had significantly higher LTBI sensitivity and NPV and equal specificity and PPV compared to QFT GIT QFT GIT had decreased in sensitivity over age 75, whereas no loss in sensitivity was seen with QFT Plus Positive TB2 test results significantly increased the sensitivity of QFT Plus, from 86.4% to 100.0% (P=0.004) 30 15
16 Japanese IGRA Comparison LTBI trial among patients with rheumatoid arthritis Igari H, Ishikawa S, Nakazawa T, Oya Y, Futami H, Tsuyuzaki M, Suzuki K, Matsumura R Infect Chemother Feb;24(2): doi: /j.jiac N=154 Average age 66.5 years Compared results by assay type and CD4 and CD8 response 63% on steroids, 53% on biologic agents, 76% on methotrexate Assay type Positive (%) Negative (%) Indeterminate (%) QFT-Plus 15 (9.7) 138 (89.6) 1 (0.7) * TSpot-TB 7 (4.5) 143 (92.9) 4 (2.6) *P>0.05 Estimated Japanese LTBI prevalence for age yrs (2015, Matsumoto): 10.6% -15% QFT-Plus positive rate significantly higher than TSPOT but lower than expected age group prevalence Higher QFT-Plus + rate was not driven by CD8 tube (TB2) suggests these patients are not newly infected or in the process of developing active TB Positive rates impacted by CD4 and CD8 count of both assays (Indication: careful interpretation of negative results ) 31 Period 1 Period 2 One-Year Experience with QuantiFERON-TB Gold Plus in Patients with Immunosuppressive Conditions (Spain) A. Fernandez-Blazquez et al, Am J Respir Crit Care Med 2018;197:A5549, Study Design: Assessment of QFT-Plus by comparing results from 2 periods of head to head testing of patients with QFT-GIT and T-Spot.TB (5/15 to 6/16) vs QFT-Plus and TSTB (7/16 to 7/17) Risk factors: HIV, hematologic diseases, inflammatory bowel disease, rheumatic disease, candidates for biological therapy % Positive % Indeterminate Agreement Kappa QFT-GIT 14.33% %, 0.53 TSTB N=1535 p< % 8.47 p< QFT-Plus %* 0.61* N=1464 p< TSTB FINDINGS Significantly higher agreement between QFT-Plus and TSTB Significantly lower indeterminate rates by both QFTs compared to TSTB Authors conclusion: The performance of QTF-Plus improves that of QTF-GIT, achieving substantial strength of agreement with TSTB. Poster ATS
17 QuantiFERON TB Gold Plus in renal transplantation receiving immune suppressive agents (Japan) H Igari et al, Am J Respir Crit Care Med 2018;197:A5548, Study Design: 113 renal transplantation patients tested with QFT-Plus. Percentage of CD4 T- cell or CD8 T-cell was determined by flow cytometry N=113 Mean age 49 yrs (44-63) % Positive % Indeterminate QFT-Plus TB2 4.4 TB1 5.3 FINDINGS Patients with CD8 T-cell >=600/μL and CD4/CD8 ratio <1.0 had significantly higher positive rates. CD8 T-cell counts showed a positive correlation with IFN-gamma production in TB-1 and TB-2, however, CD4 counts did not. QFT-Plus had significantly lower indeterminate rates compared to elispot Authors conclusion: QFT-Plus positive rate of 5.3% is acceptable in consideration of Japanese TB statistics. Our result demonstrated the CD8 T-cell dominant immune response to TB specific antigen in the patients of renal transplantation Poster ATS Summary QFT-Plus is an improved version of QFT-GIT and moving the field of LTBI forward CD8 responses correspond to new infection in contacts, exposure and TB burden in active TB (Barcellini 2016, Petruccioli 2017, Knierer 2017) Compared to QFT_GIT, QFT-Plus with higher sensitivity in the elderly (Chien 2018, Fukushima-2018 in press) Unlike QFT-GIT, QFT-Plus results are not impacted by HIV status and less impacted by CD4 count (Telisinghe 2017, Walles 2018 pregnancy study, Fukushima 2018) In direct comparison studies in active TB and rheumatoid arthritis patients, QFT-Plus is significantly more sensitive than elispot (2018 Fukushima 2018, Igari 2018) 34 17
18 The future QFT-Plus moving the field of LTBI forward: Research questions CD8 responses as a biomarker of new infection biomarker of incipient TB? Will TB2 and CD8 response have clinical utility? The CD8 signal: Is there a quantitative threshold that is significant? 2 antigen tubes=2 results in one test: 1. What is its utility in maximizing specificity in low risk persons being tested? 2. Will test conversion that signifying new infection be more evident? Will QFT-Plus perform better in young children as it does in the extreme elderly? 35 Using QFT-Plus results: case scenarios Sample to Insight 18
19 Golden Rules: NEVER use a TST or IGRA to: Rule out disease in TB suspects (symptoms, abnormal CXR or physical finding suspicious of TB) Rule out LTBI in immunocompromised individuals in the setting of high exposure and high risk of disease progression (e.g., HIV, children under 5, transplant patients, those on immunosuppressive drugs) NO TEST CAN REPLACE CLINICAL JUDGMENT!!!! TB EXPOSURE SCENARIO: CONTACT INVESTIGATION Scenario 1: In a S. American country, a rheumatologist has 3+ smear positive active cavitary tuberculosis and coughing for 2 months She takes the contact investigation upon herself. Her strain is pansusceptible She has 2 daughters (age 1 and 3), a baby sitter and husband in her home and visits with her sister frequently. QFT-Plus is performed Sample to Insight 38 19
20 TB EXPOSURE SCENARIO: CONTACT INVESTIGATION Scenario 1: In a S. American country, a rheumatologist has active cavitary tuberculosis and coughing for 2 months She has 2 daughters (age 1 and 3), a baby sitter and husband in her home and visits with her sister frequently. QFT-Plus is performed 6/18 Husband: Positive Babysitter: Positive Sister: Positive 2 daughters: Negative Babysitter s 6 yr old child: Negative (occasional contact) CXRs performed on all household contacts: NORMAL Isoniazid started on husband, babysitter, sister and 2 children (All asymptomatic with normal examinations) Is primary prophylaxis of the QFT-negative daughters warranted? YES, consistent with US and WHO guidelines What next? Sample to Insight 39 TB EXPOSURE SCENARIO: CONTACT INVESTIGATION Scenario 1: Examining the QFT results Initial QFT June 2018 and repeated Sept 2018 Daughter age 3 Check list: Control values Consistency of TB1 and TB2 Change in values between tests? Conversion? Weak or strong? Findings: Nil close to zero Healthy mitogen responses Healthy conversion from 0.02 to >2 iu/ml Diagnosis: LTBI, recent conversion Clinical management: Complete 9 months INH 40 20
21 QuantiFERON-TB Gold Plus (QFT-Plus) Interpretation of QFT-Plus results (1) Nil (IU/ml) TB1 minus Nil (IU/ml) and 25% of Nil Any >8.0 Any <0.35 OR 0.35 and <25% of Nil TB2 minus Nil (IU/ml) Mitogen minus Nil (IU/ml) QFT-Plus result Report/ Interpretation Any Any Positive M. tuberculosis infection likely 0.35 and 25% of Nil 0.5 Negative M. tuberculosis infection NOT likely <0.5 Indeterminate Likelihood of M. tuberculosis infection cannot be determined Note: Cutoffs have not changed from QFT: revalidated 0.35 as most clinically relevant. Positive results by TB1, TB2, or both are considered positive. 1. QuantiFERON-TB Gold Plus (QFT-Plus) ELISA Package Insert. Rev. 02. February Systematically assessing both qualitative and quantitative results 1. Review control values to: Assess the quality of the host response Assess potential technical error What to expect in a healthy patient with NO risk of false negative or indeterminate? Nil value close to zero Mitogen value near 10 IU/ml or above 2. Review quantitative values of antigen (TB1 and TB2) to: Assess values in light of control results Assess potential technical error (eg. TB1>>>TB2) What to expect? TB1 and TB2 values should be close in value, or TB2>TB1 21
22 TB EXPOSURE SCENARIO: CONTACT INVESTIGATION Scenario 1: Examining the QFT results Initial QFT June 2018 and repeated Sept 2018 Daughter age 1 Check list: Control values Consistency of TB1 and TB2 Change in values between tests? Findings: Nil closer to zero than 8.0 IU/ml Healthy mitogen responses Missing: 3 of 4 TB1 and TB2 values Documented transmission hence, Important to ensure Diagnosis: LTBI unlikely Clinical management: 1. Obtain all TB1 and TB2 quantitative values 2. If values close to zero, stop INH 3. If values close to cut point consider continuing INH? ---conservative approach in setting with known transmission and highly vulnerable contact 43 TST and IGRA test interpretation: false-negative or indeterminate results Host factors affecting TST and likely IGRAs HIV- low CD4, no ARVs Recent TB infection (<8 weeks) Infections (viral, fungal, bacterial) Other illness affecting lymphoid organs Live virus vaccination Immunosuppressive drugs Overwhelming TB Malnutrition Age (<2 years, elderly) Does our patient have any of these factors? 22
23 TB EXPOSURE SCENARIO: CONTACT INVESTIGATION Scenario 1: Examining the QFT results Initial QFT June 2018 and repeated Sept 2018 Husband Check list: Control values Consistency of TB1 and TB2 Change in values between tests? Findings: Positive, valid but unusual Nil value high but closer to zero than 8 IU/ml (cut point for nil indeterminate) Mitogen response lower than expected TB1 and TB2 values >25% the nil value and perfect duplication of results Diagnosis: LTBI Clinical management: 1. No change in INH treatment 45 Indeterminate QFT results Causes High Nil (> 8 IU/ml) Mitogen Nil < 0.5 IU/ml May indicate: Excessive levels of circulating IFN- (e.g., another infection) Presence of heterophile antibody Incorrect sample handling Very rare Over vigorous shaking at high temperatures Disturbing material on surface of gel when sampling for ELISA In clinical studies*, < 0.25% of subjects had IFN- > 8 IU/ml for Nil May indicate: Incorrect sample handling > 16 hours from blood specimen draw to incubation Transportation / incubation at incorrect temperature Inadequate shaking of tubes- most common cause Overfilling of tubes 23
24 Key points Summary: Highly infectious index case with contacts under age 5, known transmission (QFT conversion of 3 yr old, totaling 4/5+ contacts) Conservative approach: ensure reviewing quantitative as well as qualitative results, especially when the patient is vulnerable to false-negative results. Any immune response may be helpful in making a clinical decision Test conversion was not subtle: both TB1 and TB2 values went from near zero to >1.9 IU/ml indicating true conversion Doctors are not robots: Decision to test is a decision to think! (John Bernardo MD, Boston) Use clinical patient information, risks and a systematic approach to review quantitative results to make final management decisions Seeking help and consultation This doctor has been using QFT-Plus to monitor progress of active TB treatment. He notices fluctuations and wants to know why. What s missing from the data that was sent? Nil and Mitogen control values Clinical information about TB risk, co-morbidities, nutritional status, and clinical response to treatment What s available in the literature? 48 24
25 Effect of tuberculosis treatment on newly developed QuantiFERON- TB Gold Plus Kamada, Arisu et al, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan P1174, 2016 ATS Quantitative results (IU/mL) During Treatment N=38 Significant decreases of interferon gamma responses were observed during treatment of active TB in both TB1 and TB2 tubes in the first 3 months. The delta (TB2-TB1) between tubes was statistically significant in the latter half and throughout treatment (P=<.05). The finding suggests CD8+ responses (represented by the difference between the 2 tubes) declined with TB treatment 49 Seeking help and consultation This doctor has been using QFT-Plus to monitor progress of active TB treatment. He notices fluctuations and wants to know why. Is it appropriate to use QFT-Plus for monitoring treatment? NO! Like the TST, IGRAs should not be used for treatment monitoring until there is more evidence 50 25
26 Summary Although better than TST, IGRAs are not panaceas: Doctors must remain doctors and use their clinical assessment Interpretation and management of IGRA results is optimized when the following is taken into consideration: Quantitative values of controls and antigen tubes Risk of infection and population prevalence of LTBI Risk of disease progression or potential bad outcome if LTBI is missed Risk vs. benefit of treatment The CD8 response may be helpful in assessing where a patient falls in the TB spectrum of infection to disease QFT Plus is moving the field forward in LTBI: providing more information than prior IGRAs with the new CD8 antigens and 2 nd antigen tube New evidence continues to be favorable for QFT Plus, especially in immunocompromised populations 51 THANK YOU FOR YOUR ATTENTION! Title, Location, Date 52 26
Approaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationLaboratory Updates on IGRA Testing
Laboratory Updates on IGRA Testing Edward A. Graviss, PhD, MPH, FIDSA August 18, 2017 EXCELLENCE EXPERTISE INNOVATION Edward A. Graviss, PhD, MPH, FIDSA, has the following disclosures to make: No conflict
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationQuantiFERON-TB Gold Plus
QuantiFERON-TB Gold Plus A New Interferon-γ Release Assay (IGRA) for the Indirect Detection of Mycobacterium tuberculosis HOT TOPIC / 2018 Presenter: Elitza S. Theel, PhD, D(ABMM) Director of Infectious
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationInterpretation of TST & IGRA results. Objectives
Interpretation of TST & IGRA results Randall Reves, MD, MSc Volunteer Clinician Denver Metro TB Program and Division of Infectious Diseases, Department of Medicine University of Colorado Denver Objectives
More informationEvidence-based use of the new diagnostic tools for TB-infection
Evidence-based use of the new diagnostic tools for TB-infection Roland Diel, MD, MPH German Central Committee against Tuberculosis, Germany 20. Tuberkulose-Symposium in Münchenwiler, 24 th March 2011 1
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2019 Bob Belknap M.D. Director, Denver Metro TB Program Disclosures No relevant financial relationships Objectives Be able to
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationInvestigation of false-positive results by the QuantiFERON-TB Gold In-Tube assay
JCM Accepts, published online ahead of print on 11 July 2012 J. Clin. Microbiol. doi:10.1128/jcm.00730-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Investigation of false-positive
More informationConflict of Interest Disclosures:
Mady Slater, M.D. Stanford University Medical Center Division of Infectious Diseases 04/23/14 WOEMA webinar Conflict of Interest Disclosures: I have no financial relationships with commercial entities
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2018 Bob Belknap M.D. Director, Denver Metro TB Program No Disclosures Objectives be able to describe: 1. Who should get tested
More informationAT HIGH RISK OF PROGRESSING TO ACTIVE TB? Senior Lecturer and Consultant Physician University Hospitals of Leicester UK
HOW WELL DO IGRAS PERFORM IN THE IDENTIFICATION OF PERSONS WHO ARE AT HIGH RISK OF PROGRESSING TO ACTIVE TB? Dr Pranab Haldar MD MRCP Senior Lecturer and Consultant Physician University Hospitals of Leicester
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationCategory Description / Key Findings Publication
PUBLICATIONS Selected T-SPOT.TB test publications, by area of interest, up to 31 th August 2016. Category Description / Key Findings Publication Background A useful primer on the evolution, administration
More informationDiagnostic challenges of active childhood TB in Tanzania. Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre
Diagnostic challenges of active childhood TB in Tanzania Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre 1 Diagnosis of Childhood Tuberculosis Muheza hospital, TZ Hilleroedhospital.dk
More informationIGRA Test Reliability. How Test Design and Lab Control Impact Results
IGRA Test Reliability How Test Design and Lab Control Impact Results IGRA Test Reliability Background Why IGRAs are uniquely challenging to both test manufacturers and labs Why complexity exists with both
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationScreening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:
TB Infection Diagnosis Recommendations Talk Developed by Lisa Y. Armitige, MD, PhD Medical Consultant, Heartland National TB Center Associate Professor Internal Medicine/Pediatrics/Infectious Disease UT
More information결핵노출접촉자감염관리 서울아산병원감염내과 김성한
결핵노출접촉자감염관리 서울아산병원감염내과 김성한 TB incidence (2012) TB incidence South Korea 108 China 73 Taiwan 68 Portucal 26 Japan 19 Spain 14 US 3.6 * unit- per 100,000 population Adapted from WHO Adapted from WHO Emerg
More informationUpdate on IGRA Predictive Value
Update on IGRA Predictive Value Sandra Kik, PhD Molebogeng Rangaka, MD, PhD Madhukar Pai, MD, PhD McGill International TB Centre, McGill University University of Cape Town & London School of Hygiene and
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More informationRichard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012
Global l Applications of IGRAs Richard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012 Disclosure I have no personal financial conflicts of I have no personal
More informationUtility of PPD or IGRA to answer the age old question of "TB or not TB
Utility of PPD or IGRA to answer the age old question of "TB or not TB Thomas S. Alexander, Ph.D., D(ABMLI) Immunologist Summa Health alexandt@summahealth.org Yes, The reservation is in the name of Dr.
More informationScreening of HIV-Infected Patients with IGRAs for LTBI. Background. Tuberculosis is the most prevalent in the world.
Screening of HIV-Infected Patients with IGRAs for LTBI Kentaro Sakashita, Akira Fujita, Shuji Hatakeyma Stay strong, Japan! Tokyo Metropolitan Tama Medical Center Department of Pulmonary Medicine Background
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationTesting & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat?
NECHA 11/4/2016 Testing & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat? E. Jane Carter, M.D. Immediate Past President International Union Against TB and Lung Disease
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationLiterature Overview. Health Economics. Experience with QuantiFERON -TB Gold. Cellestis Clinical Guide series
Literature Overview Experience with QuantiFERON -TB Gold Health Economics Cellestis Clinical Guide series 2008 www.cellestis.com This literature overview is intended to provide healthcare professionals
More informationVariation in T-SPOT.TB spot interpretation between independent observers of different laboratories
8 Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories Willeke P.J. Franken 1, Steven Thijsen 2, Ron Wolterbeek 3, John J.M. Bouwman 2, Hanane el Bannoudi
More informationOngoing Research on LTBI and Research priorities in India
Ongoing Research on LTBI and Research priorities in India Dr. C.Padmapriyadarsini, MD, MS ICMR-National Institute for Research in Tuberculosis Chennai, India Technical Consultation Meeting on Programmatic
More informationContact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan
Contact Follow-Up and Treatment of LTBI in Households of Infectious Cases in Pakistan 17 th Annual Conference, The Union-North American Region, Vancouver, Canada. 28 February 2013 Farhana Amanullah Director
More informationThe Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over?
The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over? ROY F. CHEMALY, MD, MPH, FIDSA, FACP PROFESSOR OF MEDICINE DIRECTOR, INFECTION CONTROL SECTION
More informationIGRAs for Diagnosis of Tuberculosis: 2010 Update
IGRAs for Diagnosis of Tuberculosis: 2010 Update Nira Pollock, M.D., Ph.D. Division of Infectious Diseases Beth Israel Deaconess Medical Center Boston, MA May 1, 2010 Problems with the PPD False positives
More informationGuidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors
Summary and Goals On November 13, 2012, the OPTN/UNOS Board of Directors approved a requirement that all potential living kidney donors undergo evaluation for infection with Mycobacterium tuberculosis
More informationUnderstanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
More informationTitle: Role of Interferon-gamma Release Assays in the Diagnosis of Pulmonary Tuberculosis in Patients with Advanced HIV infection
Author's response to reviews Title: Role of Interferon-gamma Release Assays in the Diagnosis of Pulmonary Tuberculosis in Patients with Advanced HIV infection Authors: Adithya Cattamanchi (acattamanchi@medsfgh.ucsf.edu)
More informationThe Most Widely Misunderstood Test of All
The Most Widely Misunderstood Test of All Lee B. Reichman, MD, MPH NJMS Global Tuberculosis Institute History of Treatment of Latent Tuberculosis Infection For more than 4 decades, treatment of persons
More informationTuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationState of the State in TB Control
State of the State in TB Control Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center Disclosures-Funding NIH (grant)
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director SF, North Coast and East Bay AETC January 8, 2015 ACCREDITATION
More informationTuberculosis and cancer
Tuberculosis and cancer David P. Holland, MD, MHS Chief Clinical Officer, CDPB Fulton County Department of Health and Wellness Assistant Professor, Emory University Disclosures No relevant financial disclosures
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationPredictive Value of interferon-gamma release assays for incident active TB disease: A systematic review
Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review Lele Rangaka University of Cape Town, South Africa mxrangaka@yahoo.co.uk 1 The 3 I s Isoniazid preventive
More informationDimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2011, p. 2102 2108 Vol. 18, No. 12 1556-6811/11/$12.00 doi:10.1128/cvi.05299-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationNew Standards for an Old Disease:
New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At
More informationMaking the Diagnosis of Tuberculosis
Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Childhood Tuberculosis Kim Smith, MD, MPH April 6, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationJeffrey R. Starke, M.D. has the following disclosures to make:
AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationResearch Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012
Research Methods for TB Diagnostics Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Overview Why do we need good TB diagnostics? What works? What doesn t work? How
More informationLatent TB Infection (LTBI)
Latent TB Infection (LTBI) Diagnosis & Treatment of Latent TB Infection (LTBI) Amee Patrawalla MD MPH Assistant Professor UMDNJ-New Jersey Medical School Infection with Mycobacterium tuberculosis without
More informationATS/CDC Guidelines for Treating Latent TB Infection
TB Intensive Tyler, Texas June 2-4, 2010 ATS/CDC Guidelines for Treating Latent TB Infection Timothy R. Aksamit, MD June 2, 2010 ATS/CDC Guidelines for Treating LTBI Tuberculosis Intensive University of
More informationLTBI conception definitions and relevance for diagnostic products
LTBI conception definitions and relevance for diagnostic products Frank Cobelens Amsterdam Institute for Global Health and Development Amsterdam, Netherlands KNCV Tuberculosis Foundation The Hague, Netherlands
More informationLatent TB, TB and the Role of the Health Department
Latent TB, TB and the Role of the Health Department Elaine Darnall, RN, BSN, CIC TB Nurse Consultant Illinois Dept of Public Health March 21, 2018 Elaine Darnall has disclosed that there is no actual or
More informationDiagnosis & Management of Latent TB Infection
Diagnosis & Management of Latent TB Infection Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director Academics, Industry: Research, Diagnosis, Public Health, Academics Adviser: Laboratory Operations,
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationLATENT TUBERCULOSIS. Robert F. Tyree, MD
LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION
More informationThe evolving concept of LTBI diagnosis tests for incipient TB and tests for persistent infection
The evolving concept of LTBI diagnosis tests for incipient TB and tests for persistent infection Frank Cobelens f.cobelens@aighd.org KNCV Tuberculosis Foundation The Hague, Netherlands Amsterdam Institute
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationFirst evaluation of QuantiFERON-TB Gold Plus performance in contact screening
ORIGINAL ARTICLE TUBERCULOSIS First evaluation of QuantiFERON-TB Gold Plus performance in contact screening Lucia Barcellini 1, Emanuele Borroni 1, James Brown 2, Enrico Brunetti 3, Daniela Campisi 4,
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #274: Inflammatory Bowel Disease (IBD): Testing for Latent Tuberculosis (TB) Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy National Quality Strategy Domain: Effective Clinical Care
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More informationThorax Online First, published on December 8, 2009 as /thx
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold
More informationRole of the Laboratory in TB Diagnosis and Management
Role of the Laboratory in TB Diagnosis and Management Michael Pentella, Ph.D., D(ABMM), CIC Associate Director University Hygienic Lab Clinical Associate Professor, College of Public Health, University
More informationTB Intensive. San San Antonio, Texas. December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 ATS/CDC Guidelines for Treating Latent TB Infection Timothy Aksamit, MD; Mayo Clinic December 1, 2010 ATS/CDC Guidelines for Treating LTBI Tuberculosis
More informationLTBI Treatment and Anti TNF alpha
LTBI Treatment and Anti TNF alpha Therapy Julie Higashi, MD PhD Director, TB Control Section San Francisco Department of Public Health TNF alpha is important for the immune response against TB Macrophages
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationReport on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
More informationThe Origin of Swine Flu
How the Heck Do You Diagnose Tuberculosis in Children, Anyway? Jeffrey R. Starke, M.D. Professor and Vice Chairman of Pediatrics Baylor College of Medicine Houston, Texas USA The Origin of Swine Flu MAIN
More informationUse of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients*
Original Research MYCOBACTERIAL DISEASE Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients* Daniel Brodie, MD; David J. Lederer, MD, MS; Jade S. Gallardo,
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas August 2, 2011 ATS/CDC Guidelines for Treating LTBI Timothy Aksamit, MD April 6, 2011 Timothy Aksamit, MD has the following disclosures to make: No conflict of interests
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationPathogenesis of Rheumatoid Arthritis. Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi: /nrrheum
1 Pathogenesis of Rheumatoid Arthritis 2 Smolen, J. S. et al. (2012) Nat. Rev. Rheumatol. doi:10.1038/nrrheum 2012.23 Biologic therapies used in the treatment of rheumatoid arthritis 3 Etanercept Infliximab
More informationLTBI-Tuberculin skin test. T-Spot.TB Technology. QuantiFERON -TB Gold In Tube T-SPOT.TB ELISA ELISA
LTBI-Tuberculin skin test QuantiFERON -TB Gold In Tube ELISA PPD ~200 antigens 3 ml blood ESAT-6 TB 7.7 16-24 hour incubation Nil Negative control PHA Positive control Andersen et al Lancet 2000;356:1099-1104
More informationTuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas August 2-5, 2011 Pediatric TB Jeffrey Starke, MD August 5, 2011 Jeffrey Starke, MD has the following disclosures to make: Is on a data safety monitoring board for Hoffman
More information